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  Standby Emergency Treatment of malaria for travellers to low 
transmission destinations. Does it make sense or save lives? 
 
Prof  Ron Behrens MD FRCP 
London School of Hygiene and Tropical Medicine, Keppel St London 7HT 
 
The recommendation for carriage Standby Emergency Treatment for  malaria (SBET) is 
now becoming more widespread across Europe.  This follows as a replacement to the 
withdrawal of recommendations for use of malaria chemoprophylaxis, predominantly 
therefore to falling transmission of Plasmodium falciparum malaria on the successful 
malaria control programmes across S. E. Asia and S America. [1]   Travellers are 
prescribed SBET antimalarial medication to carry during their journey. The policy is 
aimed at travel to areas of low falciparum malaria transmission in the above continents, 
not at travellers to Sub Saharan Africa. They are advised to use the medication when 
malaria is suspected and prompt medical attention is unavailable, but ideally, to attend 
a medical centre within 24 h of onset of symptoms for a diagnosis, and if malaria is 
confirmed, use the medication secure in the knowledge that it is not counterfeit.  
The role of SBET has been examines by a number of experts and policy groups and is 
now being selected as first line malaria prevention strategy by a number of European 
countries and Japan. 
 
SBET was first recommended in 1988 to Swiss travellers[2] visiting Thailand and data 
from a small cohort of 1187 travellers in 1989, revealed 10% of the cohort developed a 
febrile illness of whom 1 was confirmed to have malaria.  A later German study in 1995 
followed 2867 travellers of whom 127 (4.4%) had a febrile illness and 4 had positive 
malaria antibodies (0.1% of the cohort)[3]. The most recent analysis of German 
travellers carrying SBET found 84% did not follow the recommend response to a fever 
and seek medical advice.[4]  In their cohort, the proportion of febrile travellers who , 
received appropriate malaria treatment was similar in those prescribed and carrying 
SBET to those who had not been carrying SBET, so in this study, the benefit of having 
SBET prescribed was of no clear advantage. 
In 2002 a sponsored meeting, discussed the role of SBET and included discussions of 
the role in low risk countries.  For this particular indication, no consensus was achieved  
amongst the small group for its value and role in low transmission environment, in part 
for the lack of evidence.[5]  
Subsequently the use of SBET expanded to be used through  much of S. America and 
S. E. Asia by the Swiss, Germans and Austrians[6] with other EU countries including 
Italy  and the Netherlands (L Visser personal communication)  beginning to transition 
their recommendations from chemoprophylaxis to SBET in low transmission/ P vivax In 
S.E Asia and S America. 
The prescribing and carriage of SBET has been rationalised with a number of 
explanations.[5] 
 
 Areas have inadequate medical services, and good quality medication may not 
be obtainable 
 Remote areas out of reach of medical attention within 24 h 
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 Tolerability of chemoprophylaxis. 
 Reminder to travellers they are at risk of malaria and to seek medical advice if 
febrile 
 Prevent progression of/to life-threatening illness. 
 
The successful control of and significant reduction in both transmission and more 
importantly widespread treatment of malaria in these regions calls into to question the 
concerns of diagnosis and the availability of good quality drugs[1].   Although counterfeit 
drugs have been shown to present in the marketplace of these countries, these appear 
to have not impacted on malaria control and elimination.  
 
The cost benefit and effectiveness of this strategy must be called into question. 
If we look at effectiveness first, the very limited data suggest falciparum malaria occurs 
in<10% of febrile patients in this settings and therefore presumptive or even by local 
diagnosis has a probability of being P falciparum malaria in <90% of febrile symptoms. 
The implications of a fulminant sepsis or other severe infections including bacterial 
(rickettsia, salmonella) and viral fevers being delayed or mistreated as malaria, needs 
to be considered.  Shanks has similarly argued why SBET does not resolve the main 
causes of  fever in travellers or deal completely with the commonest Plasmodia,  P. 
vivax and argues that preventative health advice should focus on trauma service rather 
than malaria treatment [7] 
The epidemiology of imported malaria from these regions [8] has shown that the risk of 
malaria in most regions is now well below 1 case of P falciparum cases per 100,000 
visits from western travellers and in many destinations such as Vietnam and Thailand 
significantly lower. Visits to single urban or resort destinations (e.g. Phuket, Chang Mai, 
Koh Samui and similar) with no risk of malaria, are not  affected  by the policy to  
receive SBET.  However a significant majority of travellers, particularly in S E Asia 
travel regionally, across  multiple countries[9], and  pass though varied risk regions, 
making SBET recommendations relevant to a large proportion of  visitors to both S. E. 
Asia and S. America.. Data from  UK  travellers to S.E Asia in 2014 shows and  
incidence of all malaria to be around   0.1 case per 100,000 visits and  only 1 case of P 
falciparum in 3.5 million visitors to 11 countries.(unpublished data). The denominator 
will include visits to cities and resort destination with no risk of malaria, so overestimate 
incidence. 
As for cost, benefit of SBET in low transmission settings.  If we use a model based on 
the decade old average incidence of acquiring P falciparum across SE Asia of 0.4 
cases per 100,000 visits,[8] the number of treatments required to be carried to treat 1 
true falciparum case would be approximately 200,000 doses.  The number of 
treatments to be carried to prevent 1 death (1% Case Fatality Rate)  would be of the 
order of 20 million doses.  Multiplying this by the cost of each treatment (~€40), the cost 
of 1 avoided death is extraordinary (20m x  €40) . Using the 2014 incidence of P 
falciparum, the cost would be 17 times higher than even this large number. 
The study by Vinnemeier et al. calculated that €71.4 million was spent by German 
tourist (~1.77 million) on SBET in 2015, in which 4 cases of P. falciparum were reported 
from the region, and a 5 year total of 13 P falciparum imported into Germany from the 
major tourist destinations in S E Asia[4].  
 
Haditsch [10] assessment on  the need SBET in low transmission countries is in part 
contingent on rapid access (24hrs) to adequate diagnosis and treatment.  However if 
the incident P falciparum rate is 1 in 3.5 million, this argument is somewhat irrelevant. 
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The main (and possibly only) beneficiary of the SBET policy is the pharmaceutical 
industry who benefit from the sale of millions of doses of treatments annually, most of 
which will be discarded. The drugs recommended include artemether/ lumefantrine, 
dihydorartemesinin/piperaquine and atovaquone/proguanil.   The choice of 
atovaquone/proguanil is somewhat surprising given its slow parasite clearance rate and 
that is not included as a treatment for falciparum malaria in endemic regions by WHO 
malaria treatment guidelines. Its inclusion may be related to its utility as a 
chemoprophylaxis, making unused tablets available for use as a chemoprophylaxis in 
future travel. 
Recommending SBET to travellers with negligible malaria risk but facing many other 
more frequent and life threatening health concerns, is a major disservice and makes 
little sense in current S. E. Asia and S. American low falciparum transmission 
destinations. 
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